Mirum Pharmaceuticals (NASDAQ: MIRM) announced that its investigational drug brelovitug met the primary endpoint in the Phase 3 portion of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE